focus -WSS

focus

author：focus 2025-10-01 00:46:19 - browse：174

Judge's gavel — Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. Adobe

WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere.

Drugmakers lost a two-decade long lobbying fight in Congress last summer when Democrats gave Medicare more power to choose what it pays for prescription drugs. Now, they’re taking their battle to the courts.

Merck filed suit in the District of Columbia. Bristol Myers Squibb filed in New Jersey. The Chamber of Commerce filed in Ohio. PhRMA filed in Texas. And there’s no reason to believe the barrage of lawsuits will stop anytime soon.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： As AI regulations shape up, health tech startups beg for clarity

WSS

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

FDA approves first new drug developed for postpartum depression

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Bispecific antibodies are next new thing in cancer immunotherapy

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

Novo: Oral version of Ozempic leads to 15% weight loss

explore

focus

leisure time

Heart attack and stroke risk calculators need revising

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Jerome Adams on the need for new antivirals for Covid

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Medical records are filled with copy

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Novavax promises a turnaround & Lilly roils the obesity market

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Medical leaders decry Supreme Court decision on affirmative action

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

hotspot

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Bispecific antibodies are next new thing in cancer immunotherapy

Bispecific antibodies are next new thing in cancer immunotherapy

WATCH: Why do our ears pop?

explore

focus

knowledge

focus